Skip to main content
Log in

The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation

Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Murie double minute 2 (MDM2) is an oncoprotein that inhibits the function of p53 tumor-suppressor protein. Although there have been a few reports onMDM2 gene abnormalities, there has been no investigation into expression of the product of this gene in esophageal squamous cell carcinoma. Thus, the clinicopathological and prognostic significance of the product of theMDM2 gene is as yet unknown.

Methods

MDM2 protein expression status was analyzed in surgically resected materials by immunohistochemical procedures.

Results

The expression of MDM2 significantly correlated inversely with tumor size, depth of invasion, lymph node metastasis, lymphatic vessel invasion, and stage of disease. However, the expression of MDM2 correlated with neither p53 protein accumulation status nor Ki-67 labeling index. The prognosis with MDM2-positive status was significantly better than that with MDM2-negative status for patients with p53-negative tumors, but not in those with p53-positive tumors. Moreover, multivariate analysis showed that the expression of MDM2 was an independent prognostic factor in patients with p53-negative tumors.

Conclusions

These findings indicate that MDM2 immunohistochemical analysis may provide useful information concerning the prognosis in esophageal squamous cell carcinoma patients with p53-negative tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cahilly-Snyder L, Yang-Feng T, Francke U, George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line.Somat Cell Mol Genet 1987;13:235–44.

    Article  PubMed  CAS  Google Scholar 

  2. Fakharzadeh SS, Truso SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.EMBO J 1991;10:1565–9.

    PubMed  CAS  Google Scholar 

  3. Olinr JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas.Nature 1992;358:2353–60.

    Google Scholar 

  4. Haines DS, Landers JE, Engle LJ, George DL. Physical and functional interaction between wild-type p53 and mdm2 proteins.Mol Cell Biol 1994;14:1171–8.

    PubMed  CAS  Google Scholar 

  5. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes.Oncogene 1993;8:2353–60.

    PubMed  CAS  Google Scholar 

  6. Esteve A, Lehman T, Jiang W et al. Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of MDM-2 amplification in human esophageal carcinomas.Mol Carcinog 1993;8:306–11.

    PubMed  CAS  Google Scholar 

  7. Shimada Y, Imamura M, Shibagaki I, et al. Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy.Ann Surg 1997;226:162–8.

    Article  PubMed  CAS  Google Scholar 

  8. Hermaneck P, Sobin LH, eds.International Union Against Cancer (UICC) TNM Classification of Malignant Tumours. 4th ed. Berlin: Springer, 1987.

    Google Scholar 

  9. Würl P, Meye A, Berger D, et al. Significance of retinoblastoma and mdm2 gene expression as prognostic markers for soft-tissue sarcoma.Langenbecks Arch Surg 1998;383:99–103.

    Article  PubMed  Google Scholar 

  10. Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M, Kaibara N. Clinicopathologic significance of the expression of mutated p53 protein and the proliferative activity of cancer cells in patients with esophageal squamous cell carcinoma.J Am Coll Surg 1997;185; 398–403.

    Article  PubMed  CAS  Google Scholar 

  11. Nakayama T, Toguchida J, Wadayama B, Kanoe H, Kotoura Y, Sasaki M. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors.Int J Cancer 1995;64:342–6.

    PubMed  CAS  Google Scholar 

  12. Marchetti A, Buttitta F, Girlando S et al. mdm2 gene alterations and mdm2 protein expression in breast carcinomas.J Pathol 1995; 175:31–8.

    Article  PubMed  CAS  Google Scholar 

  13. Jiang M, Shao ZM, Wu J, et al. p21/wafl/cip 1 and mdm-2 expression in breast carcinoma patients as related to prognosis.Int J Cancer 1997; 74:529–34.

    Article  PubMed  CAS  Google Scholar 

  14. Courjal F, Cuny M, Rodriguez C et al. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours.Br J Cancer 1996;74:1984–9.

    PubMed  CAS  Google Scholar 

  15. Habuchi T, Kinoshita H, Yamada H, et al. Oncogene amplification in urothelial cancer with p53 gene mutation or MDM2 amplification.J Natl Cancer Inst 1994;85:1331–5.

    Article  Google Scholar 

  16. Qian W, Hu LF, Chen F, et al. Infrequent MDM-2 gene amplification and absence of gross WAF-1 gene alterations in nasopharyngeal carcinoma.Eur J Cancer B Oral Oncol 1995;31:328–32.

    Article  Google Scholar 

  17. Matsumura T, Yoshihama Y, Kimura T, Shintani S, Alcalde RE. p53 and MDM2 expression in oral squamous call carcinoma.Oncology 1996;53:308–12.

    Article  PubMed  CAS  Google Scholar 

  18. Pruneri G, Pignataro L, Carboni N et al. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation.Mod Pathol 1997;10:785–92.

    PubMed  CAS  Google Scholar 

  19. Higashiyama M, Doi O, Kodama K, et al. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favorable prognostic marker in patients without p53 protein accumulation.Br J Cancer 1997;75:1302–8.

    PubMed  CAS  Google Scholar 

  20. Lianes P, Orlow I, Zhang ZF, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer.J Natl Cancer Inst 1994;86:1325–50.

    Article  PubMed  CAS  Google Scholar 

  21. Gorgoulis VG, Rassidakis GZ, Karameris AM, et al. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.Mod Pathol 1996;9:544–54.

    PubMed  CAS  Google Scholar 

  22. Courjal F, Cuny M, Rodriguez C et al. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours.Br J Cancer 1996;74:1984–9.

    PubMed  CAS  Google Scholar 

  23. Tanner B, Hengstler JG, Laubscher S, et al. mdm 2 mRNA expression is associated with survival in ovarian cancer.Int J Cancer 1997;74:438–42.

    Article  PubMed  CAS  Google Scholar 

  24. Zou M, Shi Y, Al-Sedairy S, Hussain SS, Farid NR. The expression of the MDM2 gene, a p53 binding protein, in thyroid carcinogenesis.Cancer 1995;76:314–8.

    Article  PubMed  CAS  Google Scholar 

  25. Waber PG, Chen J, Nisen P. Infrequency of MDM-2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas.Cancer Res 1993; 53:6028–30.

    PubMed  CAS  Google Scholar 

  26. McCann AH, Kirley A, Carney DN et al. Amplification of the MDM-2 gene in human breast cancer and its association with MDM-2 and p53 protein status.Br J Cancer 1995;71:981–5.

    PubMed  CAS  Google Scholar 

  27. Cordon-Cardo C, Latres E, Drobnjak M et al. Molecular abnormalities of MDM-2 and p53 genes in adult soft tissue sarcoma.Cancer Res 1994;54:794–9.

    PubMed  CAS  Google Scholar 

  28. Zhou M, Yeager AM, Smith SD, Findley HW. Overexpression of the MDM-2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.Blood 1995;85:1608–14.

    PubMed  CAS  Google Scholar 

  29. Landers JE, Haines DS, Strauss JF, III, George DL. Enhanced translation: a novel mechanism of MDM-2 oncogene overexpression identified in human tumor cells.Oncogene 1994;9:2745–50.

    PubMed  CAS  Google Scholar 

  30. Sheikh MS, Shao ZM, Hussain A, Fontana JA. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma.Cancer Res 1993; 53:3226–8.

    PubMed  CAS  Google Scholar 

  31. Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53.Cell 2000;102:849–62.

    Article  PubMed  CAS  Google Scholar 

  32. Dellas A, Schulheiss E, Almendral AC et al. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia.Int J Cancer 1997;74:421–5.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hiroaki Saito MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saito, H., Tsujitani, S., Oka, S. et al. The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation. Annals of Surgical Oncology 9, 450–456 (2002). https://doi.org/10.1007/BF02557267

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02557267

Key Words

Navigation